Dec 16, 2019
MediSieve wins Most Innovative Startup Award at BioFit Event 2019
MediSieve was selected as the most innovative startup at BioFit event in Marseille.
LONDON – December 16, 2019 – MediSieve was honoured to receive the Innovative Start-up Award in the Infection category at BioFIT in Marseille, earlier this month.
BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences.
The Start-up Slams, which MediSieve partook, are a great opportunity for young companies (and particularly start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors in the Life Sciences field. MediSieve’s application was reviewed by a jury, composed of high-level representatives and international experts from public and private institutions, life sciences industries, and investors, who selected the most innovative projects. Dr George Frodsham, founder and CEO of MediSieve said, “It’s fantastic to win this prestigious award. It’s been such an amazing year for MediSieve and this wraps up 2019 brilliantly. We look forward to all that 2020 has to bring.”
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: